Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                

Breast Cancer Screening: Screening Management:: A. Dci

Download as pdf or txt
Download as pdf or txt
You are on page 1of 1

Screening: screening Evaluation of breast masses Management:

BREAST CANCER mammography Surgery


MRI for women Radiation therapy
with genetic risk, untested Chemotherapy
first-degree relatives of premenopausal postmenopausal Targeted therapy
women with cancer, w/ hx of
radiation therapy to chest bet.
10 and 30 yrs, women with Questionable mass Dominant mass
lifetime risk of breast CA of “thickening”
at least 20%

Risk factors: early menarche Mass Aspiratio


Reexamine at
Late first full-term pregnancy persists n
follicular phase
Late menopause
of menstrual
Central obesity
cycle cyst Solid mass Mammogram
Moderate alcohol intake
Depression
Long term use of hormone
replacement therapy Mass gone Nonbloody Blood Suspicious Benig
Radiation before age 30 y

Routine Mammog
ram and Management by triple FNA
screening Biopsy diagnosis or biopsy
biopsy B

Observe
Invasive Non-invasiv A. DCI
S

Breast CA Metastatic:
- palliative
Follow-up:
* History; eliciting symptoms; PE every 3-6months
for 3 years; every 6-12 months for 2 years; then
annually
* Breast self-exam monthly Stage III:
* Mammography annually Early-stage breast CA: - locally advanced: may do surgery
* Pelvic exam annually - lumpectomy - with chest wall involvement,
* Ongoing px education about symptoms of - adjuvant systemic therapies: inflammatory breast CA, CA w/ large
recurrence 1. Chemotherapy matted axillary LN: mastectomy then
* Ongoing coordination of care 2. Endocrine radiotherapy to chest wall or to the
* ongoing assessment of side effects if on 3. Anti-HER2 breast after tumor excision; regional LN
endocrine therapy therapies treatment
* ECG if on trastuzumab every 3 months; - adjuvant anti-HER2 and endocrine
discontinue when trastuzumab therapy complete therapies, as appropriate
1

You might also like